Search

CP2c-Targeting Peptide Anticancer Agent Patent Grant

USPTO granted patent US12605453B2 to Industry-University Cooperation Foundation Hanyang University on April 21, 2026, covering a CP2c-targeting peptide-based anticancer agent. The peptide binds to transcription factor CP2c to inhibit the formation of CP2c homotetramers and CP2c/CP2b/PIAS1 heterohexamers, inducing cancer cell-specific cell death. A fatty acid is bound to the peptide for in vivo stability. The patent contains 5 claims.